Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols / Ivermectina como um possível tratamento para COVID-19: uma revisão dos protocolos de 2022

Ivermectin is a safe and effective drug in humans and has been approved for use in numerous parasitic infections for over 50 years. In addition, many studies have already shown its antiviral activity. Ivermectin is generally well tolerated, with no indication of central nervous system-associated toxicity at doses up to 10 times the highest FDA-approved dose of 200 µg/kg. The in vitro results of ivermectin for reducing SARS-CoV-2 viral load are promising and show that Ivermectin kills SARS-CoV-2 within 48 hours. A hypothesized mechanism of action for this drug is a likely inhibition of IMPα/ß1-mediated nuclear import of viral proteins as demonstrated for other RNA viruses. However, controlled and randomized studies are needed to prove its effectiveness in COVID-19 in humans. In a single in vivo study with published results, patients confirmed to be infected with SARS-CoV-2 received at least one dose of ivermectin at any time during hospitalization. The use of ivermectin was associated with lower mortality during treatment with COVID-19, especially in patients who required increased inspired oxygen or ventilatory support. Additionally, 81 studies with the clinical use of ivermectin in humans are being carried out worldwide according to ClinicalTrials.gov. However, none of these data has been published so far. However, private and public entities in Brazil have been adopting this drug in their protocols as prophylaxis and in the initial phase of the disease. In addition, ivermectin has been used in mass treatment to prevent onchocerciasis and lymphatic filariasis in sub-Saharan Africa for many years. Surprisingly, this region has the lowest proportional mortality rate among the continents, despite the increasing numbers of infected people released by the World Health Organization.

A ivermectina é um fármaco seguro e eficaz em seres humanos e é aprovado para uso em inúmeras infecções parasitárias há mais de 50 anos. Além disso, muitos estudos já evidenciaram sua atividade antiviral. A ivermectina é geralmente bem tolerada, sem indicação de toxicidade associada ao sistema nervoso central para doses até 10 vezes a dose mais alta, aprovada pelo FDA (Food and Drug Administration), de 200 µg/kg. Os resultados in vitro da ivermectina para redução da carga viral do SARS-CoV-2 são promissores e mostram que a Ivermectina mata o SARS-CoV-2 dentro de 48 horas. Uma hipótese de mecanismo de ação para esta droga é uma provável inibição da importação nuclear de proteínas virais mediada por IMPα / ß1 como demonstrado para outros vírus de RNA. No entanto, estudos controlados e randomizados são necessários para comprovar sua eficácia na COVID-19 em humanos. Em um único estudo in vivo com resultados publicados, pacientes confirmadamente infectados por SARS-CoV-2 receberam pelo menos uma dose de ivermectina em qualquer momento durante a hospitalização. A utilização da ivermectina foi associada a menor mortalidade durante o tratamento com COVID-19, especialmente em pacientes que necessitaram de maior oxigênio inspirado ou suporte ventilatório. Adicionalmente, 81 estudos com o uso clínico da ivermectina em humanos estão sendo realizados em todo o mundo segundo o site ClinicalTrials.gov. Porém, nenhum destes teve seus dados publicados até o momento. No entanto, entidades privadas e públicas no Brasil vêm adotando este medicamento em seus protocolos como profilaxia e na fase inicial da doença. Além disto, a ivermectina é utilizada no tratamento em massa na prevenção da oncocercose e filariose linfática na África subsaariana há muitos anos. Surpreendentemente, esta região possui o menor índice de mortalidade proporcional entre os continentes, apesar dos números crescentes de contaminados divulgados pela Organização Mundial da Saúde.

Ivermectin as a possible treatment for COVID-19: a review of the 2022 protocols.

Ivermectin is a safe and effective drug in humans and has been approved for use in numerous parasitic infections for over 50 years. In addition, many studies have already shown its antiviral activity. Ivermectin is generally well tolerated, with no indication of central nervous system-associated toxicity at doses up to 10 times the highest FDA-approved dose of 200 µg/kg. The in vitro results of ivermectin for reducing SARS-CoV-2 viral load are promising and show that Ivermectin kills SARS-CoV-2 within 48 hours. A hypothesized mechanism of action for this drug is a likely inhibition of IMPα/ß1-mediated nuclear import of viral proteins as demonstrated for other RNA viruses. However, controlled and randomized studies are needed to prove its effectiveness in COVID-19 in humans. In a single in vivo study with published results, patients confirmed to be infected with SARS-CoV-2 received at least one dose of ivermectin at any time during hospitalization. The use of ivermectin was associated with lower mortality during treatment with COVID-19, especially in patients who required increased inspired oxygen or ventilatory support. Additionally, 81 studies with the clinical use of ivermectin in humans are being carried out worldwide according to ClinicalTrials.gov. However, none of these data has been published so far. However, private and public entities in Brazil have been adopting this drug in their protocols as prophylaxis and in the initial phase of the disease. In addition, ivermectin has been used in mass treatment to prevent onchocerciasis and lymphatic filariasis in sub-Saharan Africa for many years. Surprisingly, this region has the lowest proportional mortality rate among the continents, despite the increasing numbers of infected people released by the World Health Organization.

Bradicardia extrema por infarto talámico paramediano bilateral / Extreme bradycardia due to bilateral paramedian thalamic infarction

RESUMEN Alteraciones autonómicas agudas por infartos cerebrales se han descrito con frecuencia comprometiendo la región insular, dentro de las anormalidades se han documentado alteraciones de severidad variable del ritmo cardíaco, incluyendo la bradicardia extrema sintomática; en la literatura solo hay un reporte de caso de bradi-cardia extrema asociado a un infarto talámico paramediano bilateral, a continuación, describimos un segundo caso de un infarto talámico con la misma presentación.

SUMMARY Acute autonomic disturbances due to cerebral in farcts has been describe frequently with association of the insular cortex, within the describe abnormalities had been document a variety of cardiac disturbances including extreme symptomatic bradycardia; In the literature just exist a case report of extreme bradycardia associate with a bilateral paramedian thalamic infarct, in the following article, we describe a second case of this infarct with the same presentation.

The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.

OBJECTIVES: To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women. METHODS: A systematic literature review was performed. We searched the following electronic databases: Medline, Cochrane, Embase, Lilacs, CINHAL and Google Scholar. The studies selected included controlled clinical trials and quasi-experimental studies. Selections were made in pairs and independently, first by title and abstract and then complete texts. RESULTS: We identified 188 studies, 22 of which met the inclusion criteria; 13 were controlled clinical trials and nine were quasi-experimental, and 1217 women were included. These studies confirmed the efficacy of local estrogens to treat symptoms of vulvovaginal atrophy with few adverse effects reported. Following treatment, serum estriol levels rose, peaking at 1 h. At the 6-month follow-up, there was no increase in serum estriol in treated women. CONCLUSIONS: The available evidence (of low and moderate quality) shows that, when administered vaginally, estriol preparations appear to be safe for women who have risk factors related to systemic estrogen therapy.

Actividad física en residentes de medicina familiar de Bogotá y su recomendación a los pacientes / Physical Activity in Bogotá Family Practice Residents and their recommendation to Patients

Objetivo: Identificar los hábitos de actividad física (AF) en residentes de medicina familiar de Bogotá y las recomendaciones que dan sobre esta a los pacientes. Metodología: Estudio de corte transversal con aplicación de parte de la encuesta de Healthy Doctor = Healthy Patient y preguntas sobre las "Características del médico y de la práctica clínica" de la iniciativa Exercise is Medicine® en los profesionales en formación en medicina familiar de 5 universidades de Bogotá. Resultados: El total de participantes fue de 9? residentes, quienes reportaron AF vigorosa, moderada y leve. Conclusiones: Los resultados evidenciados y comparados con la literatura internacional disponible (Reino Unido, Estados Unidos, Nueva Zelanda y Canadá) muestran que hay convergencia en la necesidad de capacitar médicos de atención primaria en la forma correcta de interrogar y recomendar la AF, de forma escrita, teniendo el formato incluido en la historia clínica esto respaldado por iniciativas internacionales.

Objective: To identiíy habits and physical activity recommendations in family medicine residente of Bogotá. Methodologyt Cross

Características de pacientes ingresados a la unidad de cuidado intensivo neonatal en la Clínica Universidad de La Sabana / Features of patients hospitalized to the newborn intensive care at Clínica Universidad de La Sabana

Introducción: Es pertinente conocer las características de los pacientes que ingresan a las unidades de cuidado intensivo neonatal para que las acciones en salud respondan a sus necesidades particulares. Objetivo: Caracterizar los pacientes que ingresaron a la Unidad de Cuidado Intensivo Neonatal (UCIN) de la Clínica de la Universidad de La Sabana de enero a diciembre del 2012. Materiales y Métodos: estudio retrospectivo con n=206 neonatos que ingresaron a la UCIN de la Clínica Universidad de La Sabana en el 2012, se revisaron las historias clínicas de los pacientes ingresados para identificar sus características, se calcularon frecuencias relativas y absolutas; y para las variables cuantitativas se describieron medidas de tendencia central y dispersión. Resultados: el 56,3% eran hombres, el promedio de edad gestacional de 36,5 semanas (SD 3,3 semanas), el peso promedio fue de 2625,9 g (SD 757,5 g). La mediana de los días de estancia fue de 4 (IQR: 2 a 9). El principal diagnóstico fue ictericia neonatal en (21,8%), el 22% de los pacientes requirieron ventilación mecánica (VM). La media de la edad gestacional y del peso en pacientes con requerimientos de VM fue de 32.7 semanas (SD: 3,7 semanas) y 1883 g (SD: 779 g) respectivamente, comparado con 37,6 semanas (SD: 2,2 semanas) y 2840 g (SD: 601 g) en los que no requirieron VM. Conclusiones: características como bajo peso al nacer, edad gestacional temprana y el uso de surfactante, se asociaron con el requerimiento de VM, adicionalmente la mortalidad calculada fue del 2,8%.

Introduction: It is relevant to know the characteristics of patients who enter to neonatal intensive care units in order to learn how to respond to their specific conditions and which health actions can be applied for their particular needs. Objective: The aim of this study is describe patients admitted at Clinica Universidad de La Sabana (Neonatal Intensive Care -NIC) from January to December 2012. Materials and Methods: Retrospective study with n=206 neonates admitted to the NIC at Clinica Universidad de La Sabana in 2012, medical records of patients admitted were reviewed to identify its characteristics, as well absolute and relative frequencies were calculated. In terms of quantitative variables, they were measured with central tendency and dispersion. Results: 56.3% of patients were men, the average gestational age was 36.5 weeks (SD 3.3 weeks), the average weight was 2625 gr (SD 757.5 gr). The median days of stay was 4 (IQR:2-9). The main diagnosis was neonatal icterus (21.8%); 22% of patient's required mechanical ventilation (MV). The mean gestational age and weight in patients with VM requirements was 32.7 weeks (SD: 3.7 weeks) and 1883 gr (SD: 779 gr) respectively. Contrasted with the gestational age and weight of newborns that not requiring VM was 37.6 weeks (SD 2.2 weeks) and 2840 gr (SD: 601 gr). Conclusions: Low birth weight, early gestational age and the use of surfactant, were associated with the requirement of VM, and the mortality found was 2.8% for the whole cohort.

Relationship between phylogeny and immunity suggests older Caribbean coral lineages are more resistant to disease.

Diseases affect coral species fitness and contribute significantly to the deterioration of coral reefs. The increase in frequency and severity of disease outbreaks has made evaluating and determining coral resistance a priority. Phylogenetic patterns in immunity and disease can provide important insight to how corals may respond to current and future environmental and/or biologically induced diseases. The purpose of this study was to determine if immunity, number of diseases and disease prevalence show a phylogenetic signal among Caribbean corals. We characterized the constitutive levels of six distinct innate immune traits in 14 Caribbean coral species and tested for the presence of a phylogenetic signal on each trait. Results indicate that constitutive levels of some individual immune related processes (i.e. melanin concentration, peroxidase and inhibition of bacterial growth), as well as their combination show a phylogenetic signal. Additionally, both the number of diseases affecting each species and disease prevalence (as measures of disease burden) show a significant phylogenetic signal. The phylogenetic signal of immune related processes, combined with estimates of species divergence times, indicates that among the studied species, those belonging to older lineages tend to resist/fight infections better than more recently diverged coral lineages. This result, combined with the increasing stressful conditions on corals in the Caribbean, suggest that future reefs in the region will likely be dominated by older lineages while modern species may face local population declines and/or geographic extinction.

Thermal characterization of magnetically aligned carbonyl iron/agar composites.

Composites of magnetic particles into polymeric matrices have received increasing research interest due to their capacity to respond to external magnetic or electromagnetic fields. In this study, agar from Gelidium robustum has been chosen as natural biocompatible polymer to build the matrix of the magnetic carbonyl iron particles (CIP) for their uses in biomedical fields. Heat transfer behavior of the CIP-agar composites containing different concentrations (5, 10, 15, 20, 25 and 30% w/w) of magnetically aligned and non-aligned CIP in the agar matrix was studied using photothermal radiometry (PTR) in the back-propagation emission configuration. The morphology of the CIP-agar composites with aligned and non-aligned CIP under magnetic field was also evaluated by scanning electron microscopy (SEM). The results revealed a dominant effect of CIP concentration over the alignment patterns induced by the magnetic field, which agrees with the behavior of the thermal diffusivity and thermal conductivity. Agar served as a perfect matrix to be used with CIP, and CIP-agar composites magnetically aligned at 20% CIP concentration can be considered as promising 'smart' material for hyperthermia treatments in the biomedical field.